BrandWikiReturn

Bavarian Nordic

Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland.[4] The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.

In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for dkk19 billion (approximately US$3 billion).[6] However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.[7]

Technologies

MVA-BN

MVA-BN is a proprietary technology developed by Bavarian Nordic. It is derived from the Modified vaccinia Ankara virus. MVA-BN is characterized by the inability to replicate in human cells,[8] contrary to other vaccinia-based vaccines, which may replicate in humans, thus potentially causing severe and life-threatening side effects. Developed as the non-replicating smallpox and mpox vaccine, MVA-BN is approved in Canada as Imvamune,[9] in the European Union, as Imvanex,[10] and the United States as Jynneos.[11][12][13] The vaccine was supplied for emergency use to the U.S. Strategic National Stockpile as well as other government stockpiles.

The vaccine is being deployed worldwide to combat the 2022 mpox outbreak, leading to concerns over vaccine nationalism and hoarding by countries with pre-existing contracts.[14]

Ebola vaccine development and production

The company has worked for several years with the NIAID[15] on the development of a filovirus vaccine for Ebola and Marburg hemorrhagic fever diseases. In October 2014, following a successful pre-clinical demonstration of the combination vaccine regimen of its multivalent MVA-BN Filovirus vaccine and Crucell/Janssen's AdVac technology based on adenoviral vectors, Bavarian Nordic joined efforts with Crucell Holland B.V., one of the Janssen Pharmaceuticals companies of Johnson & Johnson to develop and manufacture this vaccine regimen intended for emergency use to help contain the outbreak in West Africa.[16][17][18] In January 2015, the company had produced the first 400,000 doses of the vaccine and the first clinical trial of the vaccine regimen was initiated in the UK, with additional trials planned in the US and Africa.[19] It was approved for medical use in the European Union in July 2020.[20]

Acquisitions

In October 2019, it was announced that Bavarian Nordic would acquire travel vaccines Rabipur(/Rabavert) for rabies and Encepur for tick-borne encephalitis (TBE) from GlaxoSmithKline (GSK).[21][22] In February 2023, it was announced that Bavarian Nordic would acquire travel vaccines Vivotif for typhoid fever and Vaxchora for cholera, in addition to a late-stage candidate for chikungunya, from Emergent BioSolutions.[23]

Marketed products and pipeline

Bavarian Nordic's marketed products and pipeline, as of June 2025.[24][25]

Associations

Bavarian Nordic is a member of the Medical Countermeasures Coalition, a group of companies, academic institutions, and other organizations dedicated to building an effective medical countermeasure enterprise through sound public policy and strong public-private partnerships.[27]

The company is a funding partner of the Bipartisan Commission on Biodefense,[28] and a former donor to the Bipartisan Policy Center.[29]

External links

References

  1. Archive.ph retrieved 8 September 2023^
  2. OMX Copenhagen 25 (OMXC25CAP) Nasdaq OMX^
  3. Executive Management BN, retrieved 8 April 2024^
  4. Hellerup, Denmark Bavarian Nordic, retrieved 6 December 2021^
  5. Annual Report 2023 Bavarian Nordic, retrieved 8 April 2024^
  6. Ian Walker. Bavarian Nordic Agrees to $2.99 Billion Private-Equity Takeover The Wall Street Journal, retrieved 2025-07-30^
  7. Sanne Wass. Bavarian Bidders Drop Takeover Offer After Investor Pushback Bloomberg News, 6 November 2025^
  8. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine Expert Review of Vaccines, 9 January 2014^
  9. Products for Human Use. Submission #144762 Register of Innovative Drugs, Health Canada, 13 June 2014, retrieved 26 June 2014^
  10. Imvanex Human Medicines, European Medicines Agency, 27 May 2016, retrieved 12 June 2016^
  11. Jynneos U.S. Food and Drug Administration (FDA), 24 September 2019, retrieved 16 October 2019^
  12. Smallpox Vaccine Supply & Strength National Institute of Allergy and Infectious Diseases (NIAID), 26 September 2019, retrieved 16 October 2019^
  13. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN) in 56-80-Year-Old Subjects PLOS ONE, 2016^
  14. Exclusive: Closure of World's Only Manufacturing Plant for Monkeypox Vaccine Raises Questions About World's Ability to Meet Rising Demand^
  15. Infectious Diseases: Filovirus Vaccine Bavarian Nordic, retrieved 29 October 2014^
  16. Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN® Ebola Vaccine Bavarian Nordic, 22 October 2014, retrieved 29 October 2014^
  17. BRIEF-Bavarian Nordic to expand collaboration with Janssen reuters-brief, 23 October 2014, retrieved 29 October 2014^
  18. Johnson & Johnson plans Ebola vaccine testing AP News, 22 October 2014, retrieved 29 October 2014^
  19. J&J, Bavarian Nordic start clinical tests in Ebola vaccine race Reuters, 6 January 2015, retrieved 12 January 2015^
  20. Johnson & Johnson Announces European Commission Approval for Janssen's Preventive Ebola Vaccine 1 July 2020, retrieved 16 July 2020^
  21. Anna Smith. GSK to divest Rabipur, Encepur to Bavarian Nordic PharmaTimes, 21 October 2019, retrieved 3 April 2020^
  22. GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic www.gsk.com, retrieved 3 April 2020^
  23. Bavarian Nordic scoops up Emergent's travel vaccines, manufacturing site in deal worth up to $380M Fierce Pharma, 15 February 2023, retrieved 20 February 2023^
  24. Pipeline Bavarian Nordic, 16 June 2025, retrieved 16 June 2025^
  25. Annual Report 2024, Our vaccines (p.9) Bavarian Nordic, retrieved 16 June 2025^
  26. Equine Encephalitis Bavarian Nordic, retrieved 16 June 2025^
  27. Member Organizations Medical Countermeasures Coalition, retrieved 2 May 2024^
  28. Sponsors / Donors Bipartisan Commission on Biodefense, retrieved 20 June 2022^
  29. 2017 Annual Report Bipartisan Policy Center, 2017, retrieved 7 July 2022^